



## OPTISCAN HAS PATENT WIN IN JAPAN

After several years of legal action and appeal, Optiscan has finally won a case to have its fibre confocal patents granted in Japan. This is another significant endorsement of Optiscan's patent portfolio, and will result in further licensing and royalty opportunities for the company.

Optiscan has already licensed its fibre confocal technology for benchtop (non miniaturized) applications in USA, Canada and Australia to a number of leading microscope companies including Olympus, Nikon, Carl Zeiss, Leica, BioRad and PerkinElmer. The recent success with the Japanese Patent Office now introduces the opportunity to extend the licensing to benchtop products sold in Japan, as well as those manufactured in Japan and sold in other world markets.

Optiscan currently earns nearly \$1 million per year from licensing of benchtop confocal microscopes for laboratory use, and this is expected to increase by up to 40% as a result of the Japanese Patent Office decision.

The licensing of benchtop applications for laboratory purposes represents the first generation of Optiscan's confocal microscope technology. In recent years, the Company has succeeded in miniaturizing the technology, enabling unique clinical and medical applications. This new generation of technology is being developed with Pentax for flexible endoscopy, and other exclusive licensing opportunities are presently being pursued.

Further information:  
Matthew Barnett, CEO  
Tel (613) 9538 3347  
matthewb@optiscan.com

Bruce Andrew, CFO  
Tel (613) 9538 3398  
brucea@optiscan.com